Oppenheimer Asset Management Inc. Raises Stock Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Oppenheimer Asset Management Inc. grew its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 24.2% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 9,588 shares of the specialty pharmaceutical company's stock after purchasing an additional 1,867 shares during the quarter. Oppenheimer Asset Management Inc.'s holdings in Jazz Pharmaceuticals were worth $1,181,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. CWA Asset Management Group LLC bought a new position in Jazz Pharmaceuticals during the third quarter worth $3,197,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Jazz Pharmaceuticals by 135.3% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 174,078 shares of the specialty pharmaceutical company's stock worth $19,394,000 after acquiring an additional 100,112 shares in the last quarter. Centre Asset Management LLC bought a new position in Jazz Pharmaceuticals during the fourth quarter worth $9,335,000. Moloney Securities Asset Management LLC bought a new position in Jazz Pharmaceuticals during the fourth quarter worth $464,000. Finally, Pacer Advisors Inc. boosted its stake in Jazz Pharmaceuticals by 15.3% during the third quarter. Pacer Advisors Inc. now owns 2,099,378 shares of the specialty pharmaceutical company's stock worth $233,892,000 after acquiring an additional 278,465 shares in the last quarter. 89.14% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research analysts recently issued reports on the stock. Robert W. Baird increased their target price on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an "outperform" rating in a research note on Monday, November 18th. Cantor Fitzgerald downgraded shares of Jazz Pharmaceuticals from an "overweight" rating to a "neutral" rating and upped their price objective for the stock from $140.00 to $150.00 in a report on Wednesday, February 26th. Royal Bank of Canada lowered their price objective on shares of Jazz Pharmaceuticals from $179.00 to $178.00 and set an "outperform" rating on the stock in a report on Wednesday, February 26th. UBS Group upgraded shares of Jazz Pharmaceuticals from a "neutral" rating to a "buy" rating and upped their price objective for the stock from $145.00 to $179.00 in a report on Friday. Finally, Morgan Stanley restated an "overweight" rating and set a $183.00 price objective (up previously from $175.00) on shares of Jazz Pharmaceuticals in a report on Friday. One analyst has rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Jazz Pharmaceuticals presently has a consensus rating of "Buy" and an average target price of $189.40.

Remove Ads

Insider Activity at Jazz Pharmaceuticals

In other news, CAO Patricia Carr sold 4,813 shares of the firm's stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $144.42, for a total value of $695,093.46. Following the completion of the transaction, the chief accounting officer now directly owns 8,237 shares in the company, valued at approximately $1,189,587.54. This trade represents a 36.88 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CMO Robert Iannone sold 7,080 shares of the firm's stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $138.60, for a total transaction of $981,288.00. Following the completion of the transaction, the chief marketing officer now owns 82,024 shares of the company's stock, valued at $11,368,526.40. This trade represents a 7.95 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 25,193 shares of company stock worth $3,533,122. 4.20% of the stock is owned by company insiders.

Jazz Pharmaceuticals Stock Performance

JAZZ traded up $2.36 during trading on Friday, hitting $138.81. 1,226,548 shares of the company traded hands, compared to its average volume of 763,953. The firm has a market cap of $8.43 billion, a P/E ratio of 19.55, a price-to-earnings-growth ratio of 1.04 and a beta of 0.44. The stock's fifty day moving average is $128.14 and its 200 day moving average is $120.00. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals plc has a one year low of $99.06 and a one year high of $148.06.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.